Clinical readout
Cabaletta's rese-cel keeps autoimmune patients off immunomodulators for a year
In phase 1/2 studies of the CAR-T therapy rese-cel, all six evaluable dermatomyositis patients held their responses for a year without immunomodulators, and all five biopsied lupus nephritis patients reached drug-free remission. Most of the 71 treated patients had no or grade 1 cytokine release syndrome. Cabaletta expects registrational myositis data in late 2027.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.